Reis et al. [34] demonstrated in a chemically induced bladder cancer animal model that OncoTherad reduced RANK/RANK-L protein levels, resulting in decreased PD-1/PD-L1 immunoreactivity, with consequent inhibition of tumor progression. Here, TNFRSF11A is linked to urinary bladder cancer.